Research programme: sexual dysfunction therapeutics - S1 Biopharma

Drug Profile

Research programme: sexual dysfunction therapeutics - S1 Biopharma

Alternative Names: S1B-3006; S1B-307; S1P-401

Latest Information Update: 30 Sep 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator S1 Pharmaceuticals
  • Developer S1 Biopharma
  • Class
  • Mechanism of Action Central nervous system modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Anorgasmia; Decreased libido; Female sexual dysfunction; Male sexual dysfunction

Most Recent Events

  • 30 Sep 2016 S1B 3006 is still in preclinical trials for Female and Male sexual dysfunction (Treatment-resistant) in USA (S1 Biopharma pipeline, September 2016)
  • 30 Sep 2016 S1B 307 is still in preclinical trials for Anorgasmia, Decreased libido and Male sexual dysfunction in USA (S1 Biopharma pipeline, September 2016)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Anorgasmia in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top